Inogen to Present at J.P. Morgan Healthcare
Conference This Week
Inogen to Announce Fourth Quarter and Full Year
2022 Financial Results on February 23, 2023
Inogen, Inc. (Nasdaq: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced unaudited preliminary revenue results for
the fourth quarter and the full year ended December 31, 2022.
The Company estimates preliminary, unaudited total revenue in
the fourth quarter of 2022 to be in the range of $87.5 million to
$88.5 million, representing year-over-year growth of 14.5% to
15.8%. Full year 2022 total preliminary, unaudited revenue is
expected to be in the range of $376.7 million to $377.7 million,
representing year-over-year growth of 5.2% to 5.5%.
Foreign exchange fluctuations are estimated to have a $1.3
million impact on preliminary, unaudited fourth quarter 2022
revenue and a $5.3 million impact on preliminary, unaudited full
year 2022 revenue.
These preliminary, unaudited results are within the previously
projected fourth quarter guidance range of $87 million to $92
million.
“Despite the prevailing macroeconomic pressures and headwinds
resulting from our efforts to continue upgrading the operating
disciplines in our DTC commercial team, preliminary fourth quarter
2022 results came in within the expectations we had shared during
our third quarter earnings call,” said Nabil Shabshab, President
and Chief Executive Officer. “We expect productivity to improve in
the near-term as the tenure of our DTC team increases and we
continue partnering with our B2B channel to manage economic
pressures. While we continue to prioritize investments to drive
medium to long-term growth, we are also diligently managing
operating expenses in support of our plans for long-term
profitability.”
Inogen to Present at J.P. Morgan Healthcare
Conference
Nabil Shabshab, President and Chief Executive Officer, will
present on Wednesday, January 11, 2023, at 10:30 a.m. Pacific Time.
During the conference and in separate sessions with analysts and
investors, the Company’s officers will refer to an updated slide
presentation. A copy of this updated slide presentation is
available on investor.inogen.com. A live webcast and archived
recording of the presentation will be available to all interested
parties through the News / Events page on the Inogen Investor
Relations website.
Quarterly Conference Call Information
Inogen will issue fourth quarter and full year 2022 financial
results after the market closes on Thursday, February 23, 2023. On
the same day, the Company will host a conference call beginning at
2:00 pm PT / 5:00 pm ET.
Individuals interested in listening to the conference call may
do so by dialing:
US domestic callers (877) 841-3961 Non-US
callers (201) 689-8589
Please reference Inogen to join the call. To listen to a live
webcast, please visit the Investor Relations section of Inogen's
website at: http://investor.inogen.com/. This webcast will also be
archived on the website for 6 months.
A replay of the call will be available approximately three hours
after the live webcast ends and will be accessible through March 2,
2023. To access the replay, dial (877) 660-6853 or (201) 612-7415
and reference Conference ID: 13735129.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical
technology company offering innovative respiratory products for use
in the homecare setting. Inogen supports patient respiratory care
by developing, manufacturing, and marketing innovative
best-in-class portable oxygen concentrators used to deliver
supplemental long-term oxygen therapy to patients suffering from
chronic respiratory conditions. Inogen partners with patients,
prescribers, home medical equipment providers, and distributors to
make its oxygen therapy products widely available allowing patients
the chance to remain ambulatory while managing the impact of their
disease.
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, Inogen’s expectations regarding its
preliminary, unaudited revenue, for full year and fourth quarter
2022; expectations for future growth and profitability;
expectations related to our sales force and productivity; and our
expectations related to management of operating expenses. Any
statements contained in this communication that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as “believes,” “anticipates,” “plans,” “expects,”
“will,” “intends,” “potential,” “possible,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to,
risks arising from the possibility that Inogen will not realize
anticipated revenue; risks related to the Company’s supply chain
and limited availability of parts used in our POCs, the risk of
further slowdowns or temporary halts to production, or cost
inflation for such components; the impact of changes in
reimbursement rates and reimbursement and regulatory policies; and
the possible loss of key employees, customers, or suppliers; the
risk that expenses and costs will exceed Inogen’s expectations. In
addition, Inogen's business is subject to numerous additional risks
and uncertainties, including, among others, risks relating to
market acceptance of its products; competition; its sales,
marketing and distribution capabilities; its planned sales,
marketing, and research and development activities; interruptions
or delays in the supply of components or materials for, or
manufacturing of, its products; seasonal variations; unanticipated
increases in costs or expenses; and risks associated with
international operations. Information on these and additional
risks, uncertainties, and other information affecting Inogen’s
business operating results are contained in its Annual Report on
Form 10-K for the year ended December 31, 2021, Quarterly Report on
Form 10-Q for the period ended September 30, 2022, and in its other
filings with the Securities and Exchange Commission. Additional
information will also be set forth in Inogen’s Annual Report on
Form 10-K for the period ended December 31, 2022, to be filed with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Inogen disclaims any
obligation to update these forward-looking statements except as may
be required by law.
The amounts set forth above are preliminary estimates. Inogen is
in the process of finalizing its results of operations for the year
ended December 31, 2022, and therefore, final results are not yet
available. These preliminary, unaudited estimates are based solely
upon information available to management as of the date of this
press release. Inogen’s actual results may differ from these
estimates due to the completion of its year-end closing procedures,
final adjustments and developments that may arise between now and
the time its financial results for the year ended December 31,
2022, are finalized. You should read Inogen’s audited consolidated
financial statements for the year ended December 31, 2022, once
they become available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230110005495/en/
Agnes Lee ir@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From May 2023 to Jun 2023
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Jun 2022 to Jun 2023